- FDA details flexibilities for new cell and gene therapies to leverage past dataThe FDA is further explaining to cell and gene therapy developers the types of prior knowledge companies can leverage for clinical, nonclinical and manufacturing-related work, according to new CBER…Endpoints · 1mo ago↗ source
- Anti-aging biotech NewLimit raises $435M at $3B+ valuationThe Bay Area startup NewLimit has closed one of biotech's largest private financings of 2026 and expects to start human testing next year for its first anti-aging drug candidate. NewLimit said…Endpoints · 1mo ago↗ source
- What’s next for VEGF? #ASCO26 offered clues, but answers will have to waitCHICAGO — Not long ago, there were hopes that a new class of cancer drugs would repeat the success of Keytruda. Instead, it seems more likely they could end up making up for its weaknesses. Many ...